Henrik Ørum
Gründer bei CiVi Biopharma, Inc.
Profil
Henrik Ørum was the founder of Exiqon A, founded in 1995, where he held the title of Director.
He was also the founder of CiVi Biopharma, Inc., founded in 2016, where he held the title of Director & Chief Scientific Officer.
Dr. Ørum's current job is as a Director at CiVi Biopharma Holdings, Inc. Dr. Ørum's former jobs include being the CSO and Director-Research & Development at PNA Diagnostics A, and being the Chief Scientific Officer & Vice President at Roche Innovation Center Copenhagen A.
Dr. Ørum received a doctorate degree from the University of Copenhagen and a graduate degree from IT-Universitetet I København.
Dr. Ørum is also the founder of Cureon A.
Aktive Positionen von Henrik Ørum
| Unternehmen | Position | Beginn |
|---|---|---|
CiVi Biopharma, Inc.
 CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Gründer | 01.01.2016 |
CiVi Biopharma Holdings, Inc.
 CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Henrik Ørum
| Unternehmen | Position | Ende |
|---|---|---|
Cureon A/S
 Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Gründer | 24.04.2008 |
| EXIQON A/S | Gründer | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Technik-/Wissenschafts-/F&E-Leiter | - |
PNA Diagnostics A/S
 PNA Diagnostics A/S Medical SpecialtiesHealth Technology PNA-Diagnostics A/S manufactures medical diagnostic equipment. The firm is a subsidiary of Applera Corp. The company is headquartered in Copenhagen, Denmark | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Henrik Ørum
| University of Copenhagen | Doctorate Degree |
| IT-Universitetet I København | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
PNA Diagnostics A/S
PNA Diagnostics A/S Medical SpecialtiesHealth Technology PNA-Diagnostics A/S manufactures medical diagnostic equipment. The firm is a subsidiary of Applera Corp. The company is headquartered in Copenhagen, Denmark | Health Technology |
Cureon A/S
Cureon A/S Pharmaceuticals: MajorHealth Technology Cureon A/S is a Danish biotech company that owns the pharmaceutical rights to a novel DNA analogue, termed LNA (Locked Nucleic Acid) which displays unprecedented affinity compared to all other DNA chemistries. The company believes that the unique properties of this novel analogue will enable oligonucleotide based therapeutics (Antisense therapy) to enter main-stream pharmaceuticals. | Health Technology |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Exiqon A/S
 Exiqon A/S Miscellaneous Commercial ServicesCommercial Services Exiqon A/S engages in the development of solutions for ribonucleic acid research and analysis through its Locked Nucleic Acid proprietary technology. Its products and services are used by researchers in academia, biotech, and pharmaceutical companies around the world to make discoveries about the correlation between gene activity and the development of disease. The company was founded by Mikael Ørum, Henrik Ørum and Troels Koch on November 1, 1995 and is headquartered in Copenhagen, Denmark. | Commercial Services |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | Health Technology |
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | Commercial Services |
